Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults, and was associated with significant improvements in lean tissue mass and pain in women. Future work will evaluate benefits of a broader range of rapamycin doses on healthspan metrics for longevity, and will aim to more comprehensively establish efficacy.
Authors
- Andy Nyquist
- Girish Harinath
- Sajad Zalzala
- Mauricio Moel
- Anar Isman
- Stefanie L. Morgan (ORCID: https://orcid.org/0000-0003-3689-3333)
- Virginia Lee
Institutions
- Ann Arbor Center for Independent Living (US)
Publication Details
- Journal
- Aging
- Published
- 2025-04-04
- DOI
- https://doi.org/10.18632/aging.206235
- Citations
- 13
- Primary Topic
- Coenzyme Q10 studies and effects
- Type
- article
- Field-Weighted Citation Impact
- 10.48